Boston, Mass. – August 9, 2019 – Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, today announced management will be attending the following investor conferences in August:
- Manny Simons, Ph.D., founder and CEO will participate in a panel “Gene Therapy: Now Comes the Hard Part” at the BTIG Biotechnology Conference on Monday, August 12 at 3:00 p.m. ET in New York City; and,
- Dr. Simons will give a company presentation at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 3:40 p.m. ET in New York City
Akouos is a precision genetic medicine company dedicated to developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear Infirmary and Lonza, Inc. For more information, please visit www.akouos.com.
Katie Engleman, 1AB